The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The drug candidate is administered through oral route. It acts by targeting APO-L1 function. Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes ...

If you’re on the fence about investing in Vertex Pharmaceuticals Incorporated or AbbVie Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making ...

Vertex Pharmaceuticals (VRTX) closed at $469.29 in the latest trading session, marking a -0.99% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.3%.

Vertex had developed the candidate as a treatment for rheumatoid arthritis, taking it as far as a midphase trial in the setting. When EIP merged with Diffusion Pharmaceuticals last year to create ...

Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on the product. The data showed 93% of treated patients ...

Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...